TScan Therapeutics, Inc. (NASDAQ:TCRX) Stock Has Average Price Target of $2.67

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) have been given a consensus recommendation of “Hold” by the eight ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $2.67.

TCRX has been the subject of a number of research reports. Lifesci Capital cut shares of TScan Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Wedbush cut shares of TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 price objective for the company. in a research note on Wednesday, September 2nd. Weiss Ratings downgraded TScan Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, September 8th. Finally, HC Wainwright lowered TScan Therapeutics from a “buy” rating to a “neutral” rating and set a $1.00 target price on the stock. in a research note on Tuesday, September 8th.

TScan Therapeutics Stock Down 6.7%

TScan Therapeutics stock opened at $0.28 on Friday. TScan Therapeutics has a fifty-two week low of $0.26 and a fifty-two week high of $2.57. The firm has a market capitalization of $18.67 million, a price-to-earnings ratio of -0.30 and a beta of 1.15. The stock’s fifty day moving average is $0.55 and its two-hundred day moving average is $0.86. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.37 and a current ratio of 3.37.

TScan Therapeutics (NASDAQ:TCRX) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.02. The business had revenue of $1.05 million during the quarter, compared to the consensus estimate of $1.88 million. TScan Therapeutics had a negative return on equity of 108.72% and a negative net margin of 1,655.35%. Analysts predict that TScan Therapeutics will post -0.79 EPS for the current fiscal year.

Hedge Funds Weigh In On TScan Therapeutics

Institutional investors have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio acquired a new stake in shares of TScan Therapeutics during the second quarter valued at $36,000. Bank of America Corp DE acquired a new position in TScan Therapeutics in the 2nd quarter valued at about $48,000. BlackRock Inc. acquired a new position in TScan Therapeutics in the 2nd quarter valued at about $975,000. Landscape Capital Management L.L.C. purchased a new position in TScan Therapeutics in the 2nd quarter valued at about $25,000. Finally, NewEdge Wealth LLC purchased a new position in TScan Therapeutics in the 2nd quarter valued at about $90,000. 82.83% of the stock is owned by institutional investors and hedge funds.

About TScan Therapeutics

TScan Therapeutics, Inc is a clinical-stage biotechnology company focused on developing T cell receptor (TCR) engineered T cell therapies for the treatment of cancer. The company’s approach is designed to equip a patient’s T cells with tumor-specific TCRs that can recognize cancer-related targets presented on the surface of tumor cells.

TScan’s research and development programs address both solid tumors and hematologic malignancies. Its platform is intended to identify and validate cancer targets and matching TCRs, which may support the development of multiple targeted cell therapies for patients whose tumors express particular antigens.